Actualités et vidéos - GENSIGHT BIOLOGICS - Anglais

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will hold its Annual General Meeting on May 13, 2025, at 2:00 pm CEST at the Company’s headquarters, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France. The General Meeting will also be webcast live for shareholders on...

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced the filing on April 7, 2025 of its 2024 Universal Registration Document (URD) in English with the French market authority ( Autorités des Marchés Financiers , or AMF). The Universal Registration Document includes in particular:...

Regulatory News: GenSight Biologics (" GenSight Biologics " or the " Company ") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of March 31, 2025, and provided a business update. "By maintaining disciplined spending controls and prioritizing expenses, we have been able to extend our...

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today confirmed that its definitive annual results for the fiscal year ended 2024 are in line with the estimated figures published on February 27, 2025. Confirmation of Results The definitive consolidated and individual accounts, which were...

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that new scientific data and analyses on the gene therapy LUMEVOQ ® will be presented at the 51 st Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS) in Tucson, Arizona, USA (March 15-20, 2025). Leading...

Regulatory News: This press release is not being made in and copies of It may not be distributed or sent, directly or indirectly, into the United States, Canada, South Africa, Japan or Australia GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the " Company "), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced today a new round of financing...

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported estimated full-year 2024 consolidated financial results 1 , as reviewed by the Audit Committee and approved by the Board of Directors on February 26, 2025. The Board of Directors will approve the final accounts on March 18,...

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211039390/en/ Evolution of Visual Acuity in the REFLECT Phase III Study (Graphic: Business Wire) GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported final efficacy and...

Regulatory News: GenSight Biologics (" GenSight Biologics " or the " Company ") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of December 31, 2024, and provided a business update. " Our recent bridge financing operations have provided us with operational flexibility as we await...

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the publication of outcomes data from five years’ follow-up of patients treated unilaterally with LUMEVOQ ® , the company’s investigational gene therapy for Leber Hereditary Optic Neuropathy (LHON) due to a mutated ND4...

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the " Company "), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced today a financing through a capital increase reserved to specialized investors by the issuance of new shares with warrants attached, for a total gross amount of c. €1.5 million (excluding the future net proceeds...

Regulatory News: GenSight Biologics (" GenSight Biologics " or the " Company ") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today provided an update on its regulatory discussions with the French medicines safety agency ( Agence Nationale de Sécurité du Médicament et des Produits de Santé or the ANSM) and on its...

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the submission of the updated regulatory file for LUMEVOQ ® gene therapy to the French medicines safety agency Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) to prepare for the restart of the...

Regulatory News: THIS PRESS RELEASE IS NOT BEING MADE IN AND COPIES OF IT MAY NOT BE DISTRIBUTED OR SENT, DIRECTLY OR INDIRECTLY, INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the " Company "), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced today the resumption of the trading...

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today provides an update on its financial and operational situation. Financial Update In the past two months, GenSight has instituted cash preservation measures, including a 40% headcount reduction mainly in Commercial teams, leading to a...

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will hold its Annual General Meeting on June 21, 2023, at 9:00 am CEST at the Company’s headquarters, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France. The General Meeting will also be webcast live for shareholders on...

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the filing of its 2022 Universal Registration Document (URD) in English with the French market authority ( Autorités des Marchés Financiers , or AMF) under the reference D.23-0406. “We are actively preparing...

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announces that on April 28, 2023, the Board of Directors re-approved its full year 2022 consolidated financial statements, as updated to reflect the Company's recent decision to withdraw its European Medicines Agency (EMA) application...

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of March 31, 2023, and provided a business update. Regulatory Pathway of LUMEVOQ ® In March 2023, as planned, GenSight submitted responses to the D180 questions from the European Medicines Agency (EMA)....

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announces that the Committee for Advanced Therapies (CAT) 1 of the Committee Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) assessed the data presented during the oral explanation 2 on...